03:19:04 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen.

Kalender

2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma 2021
2021-04-20 Bokslutskommuniké 2020
2020-09-01 Kvartalsrapport 2020-Q2
2020-06-26 Årsstämma 2020
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018
2018-08-29 Kvartalsrapport 2018-Q2
2020-10-05 08:00:00
Lifecare participating in research project awarded EUR 3,9 million from the EU
Commission for development of a bionic invisible pancreas to FORGETDIABETES. 

Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature
sensor for correct and continuous monitoring of diabetics’ blood sugar. Its
patented technology is also used as a central component in a rapid test for
Covid-19 and as a measurement unit for reading out different biomarkers.

In collaboration with six academic in Italy, France, and Germany, Lifecare has
established the project “FORGETDIABETES”. Its goal is to develop an
immuno-optimized, fully implantable, fully automated, artificial pancreas for
intraperitoneal hormone delivery, enabling an optimal glycaemic control for
type-1 diabetes patients. With the support of Lifecares sensor technology, the
user of the artificial pancreas will be supplied with the correct amount of
insulin based on continuous measuring of blood sugar. 


“This is a very ambitious and exciting research project. If it succeeds, it
eliminates the need for the user to measure blood sugar several times a day and
control insulin intake. The entire process will happen automatically, and be a
huge improvement to today’s alternatives,” says Lifecare Chief Medical Officer
Kåre Birkeland.

FORGETDIABETES has received EUR 3,9 million, just over NOK 43 million, from a
FET-Proactive announcement under the EU funding programme for research and
innovation, Horizon 2020. The funds are partitioned on the seven parties, where
Lifecare received EUR 570.000, close to NOK  6,3 million. Development,
implementation and testing of the technology is estimated to take around 4,5
years. 

“Besides the great recognition of the innovative work Lifecare and its
co-workers represent, the allocation of funds from EU funding programme for
research and innovation constitute the beginning of a new potential development
of a product based on our core technology,” says Lifecare CEO Joacim Holter. 

Lifecare is the only Norwegian company receiving funds from the EU in this
round. Previous years only two other Norwegian companies have received funding
from this program. 

“To receive funding through FET is very difficult, so the application that
Lifecare delivered to the EU was excellent. The consortium that Lifecare is part
of, FORGETDIABETES, is working with an exciting nano-technology with the
potential of changing the lives of millions of people if it succeeds, ” says
Kristin Danielsen, Executive Director – Internationalisation and the research
system at The Research Council of Norway. 

For more information, please contact:
Joacim Holter
CEO, Lifecare
joacim.holter@lifecare.no
+47 40 05 90 40

Rune Frisvold
COO, Lifecare
rune.frisvold@lifecare.no
+47 90 13 60 63

Information is available at Lifecare.no; 

https://lifecare.webflow.io/lifecares-sensorteknologi-er-sentral-i-et-forsknings
prosjekt-som-far-43-millioner-kroner-i-eu-stotte

Participants in FORGETDIABETES are:
University of Padova, Italy (coordinator), Sant’ Anna School of Advanced
Studies, Italy, Lifecare AS, Norway, Pfützner Science & Health Institute,
Germany, Centre Hospitalier Universitaire de Montpellier, France,
Forschungsinstitut der Diabetes-Akademie Bad Mergentheim, Germany, and WaveComm,
Italy.